Nov 7 (Reuters) - Metsera ( MTSR ), an obesity drug
developer, said on Friday that it has entered into an amended
merger agreement with Pfizer ( PFE ), in which the New
York-based company will acquire Metsera ( MTSR ) for up to $86.25 per
share.
Metsera's ( MTSR ) board has recommended that its shareholders
"approve the adoption of the amended Pfizer ( PFE ) merger agreement and
approve the merger with Pfizer ( PFE )."